Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Zealand reduces fees, changes abbreviated review rules

This article was originally published in SRA

Executive Summary

New Zealand’s regulatory agency Medsafe has reduced the fees payable for applications for approval of innovative new medicines and for clinical trial approvals1. While the new fees applied from 8 April, the regulatory authority is holding a consultation, and any feedback received by a 22 May deadline will be considered and may result in adjustments.

You may also be interested in...

New Zealand Proposes First Increase In Regulatory Fees Since 2006

New Zealand's medicines regulator plans to increase the fees it charges for various regulatory activities as of June this year. In 2009, the agency had reduced its fees by approximately 12% as its coffers were full and the industry was then told that there would be no changes until the surplus was cleared.

Pulling In 10 Different Directions – The Challenge Of Harmonizing Asia’s VMS Market

A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.

China CSCO Hails Rising Liver Cancer Innovation Ready To Take On World

The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts